TY - JOUR
T1 - Can We Mitigate Coronary Heart Disease Risk in Patients with Cancer?
AU - Manohar, Hasitha
AU - Potter, Adam S.
AU - Koutroumpakis, Efstratios
AU - Deswal, Anita
AU - Palaskas, Nicolas L.
N1 - Funding Information:
Dr. Koutroumpakis is supported by NIH 1RO1HL157273 and the Cancer Prevention & Research Institute of Texas RP200381.
Funding Information:
Dr. Palaskas is supported by the NIH/NCI 1P01CA261669-01, the Cancer Prevention & Research Institute of Texas (RP200670), the Sabin Family Foundation Fellowship, and the MD Anderson Department of Internal Medicine Research Development Award.
Funding Information:
Dr. Deswal is supported in part by the Ting Tsung and Wei Fong Chao. Distinguished Chair. Dr. Deswal also reports other from the American College of Cardiology, other from NIH, grants from NIH, and grants from the Cancer Prevention and Research Institute of Texas.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/8
Y1 - 2022/8
N2 - Purpose of Review: The review focuses on the shared risk factors observed between coronary heart disease and cancer, cancer therapeutics causing coronary heart disease, and potential strategies to mitigate atherosclerosis in patients with cancer. Recent Findings: The pathophysiology behind how traditional cardiovascular risk factors also contribute to cancer development and mortality is increasingly recognized. In addition, newer cancer therapies, such as immune checkpoint inhibitors, cause increased inflammation leading to increased cardiovascular events. Summary: Traditional coronary heart disease risk factors such as obesity, hypertension, diabetes, and hyperlipidemia also contribute to cancer development and worse cancer outcomes. Cancer therapeutics can also lead to atherosclerotic events in addition to the shared risk factors present at the time of cancer diagnosis. Understanding the pathophysiology, using multidisciplinary care teams, and developing machine learning algorithms for individualized patient care will help to mitigate the risk of coronary heart disease in patients with cancer.
AB - Purpose of Review: The review focuses on the shared risk factors observed between coronary heart disease and cancer, cancer therapeutics causing coronary heart disease, and potential strategies to mitigate atherosclerosis in patients with cancer. Recent Findings: The pathophysiology behind how traditional cardiovascular risk factors also contribute to cancer development and mortality is increasingly recognized. In addition, newer cancer therapies, such as immune checkpoint inhibitors, cause increased inflammation leading to increased cardiovascular events. Summary: Traditional coronary heart disease risk factors such as obesity, hypertension, diabetes, and hyperlipidemia also contribute to cancer development and worse cancer outcomes. Cancer therapeutics can also lead to atherosclerotic events in addition to the shared risk factors present at the time of cancer diagnosis. Understanding the pathophysiology, using multidisciplinary care teams, and developing machine learning algorithms for individualized patient care will help to mitigate the risk of coronary heart disease in patients with cancer.
KW - Atherosclerosis
KW - Cancer
KW - Mitigation
KW - Risk factors
UR - http://www.scopus.com/inward/record.url?scp=85130820534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130820534&partnerID=8YFLogxK
U2 - 10.1007/s11883-022-01035-5
DO - 10.1007/s11883-022-01035-5
M3 - Review article
C2 - 35624391
AN - SCOPUS:85130820534
SN - 1523-3804
VL - 24
SP - 599
EP - 606
JO - Current atherosclerosis reports
JF - Current atherosclerosis reports
IS - 8
ER -